Search Result

Isoforms Recommended:	PDE4

Results for "

PDE4B

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Autophagy (1) Bacterial (2) Endogenous Metabolite (1) HIV (2) Interleukin Related (1) NF-κB (1) Phosphodiesterase (PDE) (35) Small Interfering RNA (siRNA) (1) TNF Receptor (1)
By Research Areas:	Cancer (3) Inflammation/Immunology (23) Metabolic Disease (1) Neurological Disease (9)
Oligonucleotides:	Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Natural
Products

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147830

PDE4B-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4B-IN-3 is a potent *PDE4B* inhibitor with an IC₅₀ of 0.94 μM. PDE4B-IN-3 has anti-inflammatory activities .

HY-115687

PDE4B-IN-2	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4B-IN-2 is an orally active and selective *PDE4B* inhibitor with an IC₅₀ of 15 nM. PDE4B-IN-2 inhibits PDE4D (IC₅₀=1.7 μM). PDE4B-IN-2 exhibits potent anti-inflammatory effects .

HY-70069

GSK256066 Trifluoroacetate 1 Publications Verification	Phosphodiesterase (PDE)	Inflammation/Immunology
GSK256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor, with an IC₅₀ of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary disease .

HY-RS10223

PDE4B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDE4B Human Pre-designed siRNA Set A contains three designed siRNAs for PDE4B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDE4B Human Pre-designed siRNA Set A PDE4B Human Pre-designed siRNA Set A

HY-163604

PDE4B/D-IN-1	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4B/D-IN-1 (example 8) is a potent inhibitor of *PDE4B, with IC₅₀s of 0.07 nM and 0.09 nM for PDE4B2* and *PDE4D*, respectively .

HY-163605

PDE4B/D-IN-2	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4B/D-IN-2 (example 19) is a potent inhibitor of *PDE4, with IC₅₀s of 0.023 nM and 0.066 nM for PDE4B2* and *PDE4D*, respectively .

HY-163606

PDE4B/D-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4B/D-IN-3 (example 22) is a potent inhibitor of *PDE4, with IC₅₀s of 0.071 nM and 0.09 nM for PDE4B2* and *PDE4D*, respectively .

HY-146202

PDE4B/7A-IN-2	Phosphodiesterase (PDE)	Others
5-HT1A/5-HT7 receptor antagonist (5-HT1A Ki = 8 nM, Kb = 0.04 nM; 5-HT7 Ki = 451 nM, Kb = 460 nM) with PDE4B/PDE7A inhibitory activity (PDE4B IC₅₀ = 80.4 μM; PDE7A IC₅₀ = 151.3 μM) , its antidepressant like effect is stronger than that of escitalopram as a reference agent.

HY-146201

PDE4B/7A-IN-1	Phosphodiesterase (PDE)	Others
1 a /5-hydroxynitrile rubber 7 receptor antagonist (5-HT1 a k i = 8 nm, kb= 0.04 nm; 5-nitrile rubber 7K I = 451 nm, kb= 460 nm) has pde4b/pde7a inhibitory activity (PDE4B ic50= 80.4 μ M; Pde7a chip 50= 151.3 μ M）。 Compound 22 has a very good ability of passive penetration of biofilm and high metabolic stability in vitro. In addition, 22's pharmacological evaluation showed its pre cognitive and antidepressant properties in rat behavioral tests.

HY-121162

Mesembrine (+)-Mesembrine	5-HT Receptor Phosphodiesterase (PDE)	Neurological Disease
Mesembrine ((+)-Mesembrine) a main alkaloid that features an aryloctahydroindole skeleton. Mesembrine is a 5-HT transporter inhibitor with a K_i of 1.4 nM. Mesembrine also inhibits phosphodiesterase 4B (PDE4B) with an IC₅₀ of 7.8 μM .

HY-10469

GSK256066 1 Publications Verification	Phosphodiesterase (PDE)	Inflammation/Immunology
GSK256066 is a selective and high-affinity phosphodiesterase 4 (PDE4) inhibitor, with an IC₅₀ of 3.2 pM for PDE4B. GSK256066 is developed for the research of chronic obstructive pulmonary disease .

HY-119190

PF-06445974	Phosphodiesterase (PDE)	Neurological Disease
PF-06445974, a promising positron emission tomography (PET) lead, has exquisite potency at *PDE4B* with an IC₅₀ <1 nM. The IC₅₀ values are 36, 4.7 and 17 nM for PDE4D, PDE4A and PDE4C, respectively. PF-06445974 has good selectivity over PDE4D, excellent brain permeability, and a high level of specific binding in the "cold tracer" study .

HY-16900

Rolipram Maximum Cited Publications 12 Publications Verification (R,S)-Rolipram; (±)-Rolipram; ZK 62711	Phosphodiesterase (PDE) Bacterial HIV	Neurological Disease Cancer
Rolipram is a selective phosphodiesterases *PDE4* inhibitor with IC₅₀s of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

HY-161851

MDL3	Phosphodiesterase (PDE)	Metabolic Disease
MDL3 is a novel inhibitor of PDE4B and PDE5A. MDL3 against liver injury and inflammation and inhibits the pathological remodeling of adipose tissue .

HY-16900A

(R)-(-)-Rolipram 2 Publications Verification (R)-Rolipram; (-)-Rolipram	Phosphodiesterase (PDE)	Neurological Disease
(R)-(-)-Rolipram is the R-enantiomer of Rolipram. Rolipram is a selective inhibitor of phosphodiesterases *PDE4* with IC₅₀ of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

HY-115913

PDE4-IN-6	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-6 is a potent, safe and moderately selective *PDE4* inhibitor with IC₅₀s of 0.125 and 0.43 µM for PDE4B and PDE4D, respectively. PDE4-IN-6 can downregulate the expression level of TNF-α and IL-6. PDE4-IN-6 has potent immunomodulatory activity thereby its potential against rheumatoid arthritis. Anti-inflammatory and anti-arthritic effects .

HY-117960

Orismilast LEO-32731	Phosphodiesterase (PDE)	Inflammation/Immunology
Orismilast (LEO-32731) is an orally active and selective *PDE4* inhibitor used for the research of inflammatory diseases. Orismilast demonstrates potent inhibition of PDE4B and PDE4D subtype splice variants .

HY-16900R

Rolipram (Standard)	Phosphodiesterase (PDE) Bacterial HIV	Neurological Disease Cancer
Rolipram (Standard) is the analytical standard of Rolipram. This product is intended for research and analytical applications. Rolipram is a selective phosphodiesterases *PDE4* inhibitor with IC₅₀s of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

HY-153192

Nerandomilast BI 1015550	Phosphodiesterase (PDE)	Inflammation/Immunology
Nerandomilast (BI 1015550) is an orally active inhibitor of *PDE4B* with an IC₅₀ value of 7.2 nM. Nerandomilast has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD) .

HY-153192A

Nerandomilast dihydrate BI 1015550 dihydrate	Phosphodiesterase (PDE)	Inflammation/Immunology
Nerandomilast (BI 1015550) dihydrate is an orally active inhibitor of *PDE4B* with an IC₅₀ value of 7.2 nM. Nerandomilast (dihydrate) has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD) .

HY-147950

PDE4-IN-10	Phosphodiesterase (PDE) TNF Receptor	Inflammation/Immunology
PDE4-IN-10 (compound 7a) is a potent *PDE4* inhibitor, with an IC₅₀ of 7.01 μM for *PDE4B. PDE4-IN-10 shows selectivity, microsomal stability, inhibition of TNF-α* and no major toxicities in vitro .

HY-106003

GSK356278	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology
GSK356278 is a potent, selective, orally bioavailable and brain-penetrant inhibitor of phosphodiesterase 4 (PDE4), with pIC₅₀s of 8.6, 8.8, and 8.7 for human PDE4A, PDE4B, and PDE4D, respectively. GSK356278 has anti-inflammatory activity, and exhibits anxiolytic and cognition-enhancing effects .

HY-131707

LEO 39652	Phosphodiesterase (PDE)	Inflammation/Immunology
LEO 39652 is a dual-soft *PDE4* inhibitor with IC₅₀s of 1.2 nM, 1.2 nM, 3.0 nM and 3.8 nM for *PDE4A, PDE4B, PDE4C* and *PDE4D, respectively. LEO 39652 also inhibits TNF-α* with an IC₅₀ value of 6.0 nM. LEO 39652 is used for topical research of Atopic dermatitis (AD) .

HY-112831

Osoresnontrine 1 Publications Verification BI-409306	Phosphodiesterase (PDE)	Neurological Disease
Osoresnontrine (BI-409306) is a potent and selective *PDE9A* inhibitor, with an IC₅₀ of 52 nM, and shows weak activity against other PDEs, such as PDE1A (IC₅₀, 1.4 µM), PDE1C (IC₅₀, 1.0 µM), PDE2A, PDE3A, PDE4B, PDE5A, PDE6AB, PDE7A, and PDE10A (IC₅₀ all > 10 μM); Osoresnontrine can be used in the research of memory enhancement in CNS disorders.

HY-162583

PDE4-IN-17	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-17 (compound 4e) is a potent *PDE4* inhibitor. PDE4-IN-17 inhibits *PDE4B* and *PDE4D* with IC₅₀s of 10.0 and 15.2 nM, respectively. PDE4-IN-17 has good oral bioavailability (F=66%) and longer half-life (t_1/2=2.0 h) in SD rats .

HY-103050

ML-030 1 Publications Verification	Phosphodiesterase (PDE)	Inflammation/Immunology
ML-030 is a potent *PDE4* inhibitor, with IC₅₀ of 6.7 nM, 12.9 nM, 48.2 nM, 37.2 nM, 452 nM and 49.2 nM for PDE4A, PDE4A1, PDE4B1, PDE4B2, PDE4C1,and PDE4D2, respectively.

HY-144684

PDE4-IN-8	Phosphodiesterase (PDE) Interleukin Related	Cancer
PDE4-IN-8 (Example 5) is a potent *PDE4* inhibitor with an IC₅₀ of 0.93 nM for PDE4B2.PDE4-IN-8 has little effect on IL13 (IC₅₀=4.04 nM), IL4 (IC₅₀=36.33 nM), IFNy (IC₅₀=2394 nM) .

HY-159654

PDE4-IN-19	Phosphodiesterase (PDE)	Others
PDE4-IN-19 (compound 1) is a *PDE4* inhibitor, with IC₅₀ values of <10 nM and 10-100 nM for PDE4B1 and PDE4D3, respectively .

HY-162582

Z19153	Phosphodiesterase (PDE)	Inflammation/Immunology
Z19153 is a *PDE4* inhibitor with IC₅₀ values of 110 and 1160 nM for PDE4B1 and PDE4D7, respectively. Z19153 shows good liver protection against hepatic sepsis .

HY-100246

CI-1044 PD-189659	Phosphodiesterase (PDE)	Inflammation/Immunology
CI-1044 is an orally active *PDE4* inhibitor with IC₅₀s of 0.29, 0.08, 0.56, 0.09 μM for *PDE4A5, PDE4B2, PDE4C2* and *PDE4D3*, respectively.

HY-122942

Moracin M	Phosphodiesterase (PDE) Endogenous Metabolite NF-κB Autophagy	Inflammation/Immunology
Moracin M is a phenolic component that can be isolated from Mori Cortex, is a potent **phosphodiesterase-4 (PDE4) inhibitor with IC₅₀** values of 2.9, 4.5, >40, and >100 μM for PDE4D2, PDE4B2, PDE5A1, and PDE9A2, respectively. Moracin M has anti-inflammatory activity .

HY-144683

PF-07038124	Phosphodiesterase (PDE)	Inflammation/Immunology
PF-07038124 is a *PDE4* inhibitor with an IC₅₀ of 0.5 nM for PDE4B2. PF-07038124 shows inhibitory activities against IL-13, IL4, and IFNγ (IC₅₀=125, 4.1, 1.06 nM, respectively). PF-07038124 can be used for research of atopic dermatitis and plaque psoriasis .

HY-144683A

PF-07038124 hydrochloride	Phosphodiesterase (PDE)	Inflammation/Immunology
PF-07038124 hydrochloride is a *PDE4* inhibitor with an IC₅₀ of 0.5 nM for PDE4B2. PF-07038124 hydrochloride shows inhibitory activities against IL-13, IL4, and IFNγ (IC₅₀=125, 4.1, 1.06 nM, respectively). PF-07038124 hydrochloride can be used for research of atopic dermatitis and plaque psoriasis .

HY-128358

MR-L2	Phosphodiesterase (PDE)	Neurological Disease
MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform **phosphodiesterase-4 (PDE4)*, activates representative PDE4* long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC₅₀ of 1.2 µM .

HY-117977

FCPR03	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology
FCPR03 is a potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC₅₀ values of 60 nM, 31 nM and 47 nM for PDE4 catalytic domain, *PDE4B1* and *PDE4D7, respectively. FCPR03 displays at least 2100-fold selectivity over other PDEs* (PDE1-3 and PDE5-11). FCPR03 has anti-inflammatory, neuroprotective and antidepressant-like effects .

HY-119799

UK-500001	Phosphodiesterase (PDE)	Inflammation/Immunology
UK-500001 is an orally active inhibitor for phosphodiesterase 4 (PDE4), which inhibits *PDE4D3* (IC₅₀ is 0.28 nM), *PDE4B2* (IC₅₀ is 22.8 nM), *PDE4A4* (IC₅₀ is 26.1 nM) and *PDE4C2* (IC₅₀ is 271 nM). UK-500001 exhibits anti-inflammatory efficacy and inhibits TNF-α and IFN-γ release in human and rodent macrophagic cell lines in nanomolar levels. UK-500001 ameliorates chronic obstructive pulmonary disease (COPD) and asthma .

Moracin M	Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Moraceae Endogenous metabolite Inflammation/Immunology Disease Research Fields Morus alba Linn.	Phosphodiesterase (PDE) Endogenous Metabolite NF-κB Autophagy
Moracin M is a phenolic component that can be isolated from Mori Cortex, is a potent **phosphodiesterase-4 (PDE4) inhibitor with IC₅₀** values of 2.9, 4.5, >40, and >100 μM for PDE4D2, PDE4B2, PDE5A1, and PDE9A2, respectively. Moracin M has anti-inflammatory activity .

Mesembrine (+)-Mesembrine	Alkaloids other families Pyrrole Alkaloids Source classification Plants	5-HT Receptor Phosphodiesterase (PDE)
Mesembrine ((+)-Mesembrine) a main alkaloid that features an aryloctahydroindole skeleton. Mesembrine is a 5-HT transporter inhibitor with a K_i of 1.4 nM. Mesembrine also inhibits phosphodiesterase 4B (PDE4B) with an IC₅₀ of 7.8 μM .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83187

	PDE4B Antibody (YA2932) DPDE4; PDE 4B; PDE IVB; PDE32; PDE4B; PDE4B5; PDEIVB; Phosphodiesterase 4B	WB, FC	Human, Mouse
	PDE4B Antibody (YA2932) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2932), targeting PDE4B, with a predicted molecular weight of 83 kDa (observed band size: 95 kDa). PDE4B Antibody (YA2932) can be used for WB, FC experiment in human, mouse background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

PDE4B Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PDE4B Human Pre-designed siRNA Set A contains three designed siRNAs for PDE4B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks